{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:42:43Z","timestamp":1794465763760,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundamental research program of Shanxi province","award":["20210302123289"],"award-info":[{"award-number":["20210302123289"]}]},{"name":"Shanxi Province Science and Technology Cooperation and Exchanges Project","award":["202204041101024"],"award-info":[{"award-number":["202204041101024"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270915"],"award-info":[{"award-number":["82270915"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Fund for Science and Technology Innovation Teams of Shanxi Province","award":["202304051001021"],"award-info":[{"award-number":["202304051001021"]}]},{"name":"Shanxi Province Higher Education \"Billion Project\" Science and Technology Guidance Project","award":["BYJL010"],"award-info":[{"award-number":["BYJL010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) is a global health challenge, with early detection and risk stratification across glycemic states still unresolved. This study aimed to evaluate the performance of 18 non-invasive metabolic indices in predicting MASLD (defined as hepatic steatosis with metabolic risk factors) and significant fibrosis across glycemic states and demographic subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional analyses were performed on 2,794 individuals aged\u2009\u2265\u200920 years from the 2017\u20132020 National Health and Nutrition Examination Survey cycle, stratified by glycemic status and demographic factors. Eighteen indices were assessed: triglyceride-glucose index (TyG), TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), TyG-waist-to-height ratio (TyG-WHtR), TyG-weight-adjusted waist index (TyG-WWI), visceral adiposity index (VAI), homeostatic model assessment of insulin resistance (HOMA-IR), metabolic score for IR (METS-IR), Framingham steatosis index (FSI), fatty liver index (FLI), USFLI, Zhejiang University index (ZJU), lipid accumulation product (LAP), hepatic steatosis index (HSI), non-high-density lipoprotein cholesterol (HDL-C) to HDL-C ratio (NHHR), Nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), and BMI-aspartate aminotransferase\/alanine aminotransferase ratio and diabetes score (BARD). Associations and diagnostic performance were examined using multivariable logistic regression and receiver operating characteristic analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MASLD prevalence increased with worsening glycemic status: 40.6% in normoglycemia, 62.7% in prediabetes, and 85.5% in type 2 diabetes mellitus (T2DM). TyG-WHtR exhibited the strongest association with MASLD (odds ratio [OR] 3.83), with an even higher risk in T2DM (OR 5.58). FLI, TyG-WHtR, and NFS were associated with fibrosis, though the associations were weaker in normoglycemia. TyG-WC demonstrated the highest diagnostic accuracy for MASLD (area under the curve [AUC] 0.830), particularly in males and adults\u2009\u2264\u200950 years (AUCs 0.842\u20130.853). FLI performed consistently across glycemic strata (AUCs 0.769\u20130.821). FSI performed well in T2DM (AUC 0.823) and in males (AUC 0.829). For significant fibrosis, FLI showed the best performance, particularly in prediabetes (AUC 0.761) and T2DM (AUC 0.754). Traditional markers (FIB-4, BARD) demonstrated limited utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glycemic deterioration is strongly linked to MASLD and fibrosis. TyG-WC and FLI were the most consistent and high-performing indices across glycemic and demographic groups, supporting their use as broadly applicable non-invasive tools for individualized MASLD risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02069-w","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:47:21Z","timestamp":1766425641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Personalized MASLD and\u00a0liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"1","key":"2069_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2069_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"2","key":"2069_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5005\/jp-journals-10018-1437","volume":"14","author":"S Latif","year":"2024","unstructured":"Latif S, Ahsan T. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in persons with obesity and type 2 diabetes mellitus: a cross-sectional study. Euroasian journal of hepato-gastroenterology. 2024;14(2):129\u201333. https:\/\/doi.org\/10.5005\/jp-journals-10018-1437.","journal-title":"Euroasian journal of hepato-gastroenterology"},{"issue":"2","key":"2069_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.17925\/ee.2024.20.2.2","volume":"20","author":"D Leith","year":"2024","unstructured":"Leith D, Lin YY, Brennan P. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a deadly synergy. touchREV Endocrinol. 2024;20(2):5\u20139. https:\/\/doi.org\/10.17925\/ee.2024.20.2.2.","journal-title":"touchREV Endocrinol"},{"key":"2069_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2445780","author":"D Wang","year":"2025","unstructured":"Wang D, Miao J, Zhang L, Zhang L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med. 2025. https:\/\/doi.org\/10.1080\/07853890.2024.2445780.","journal-title":"Ann Med"},{"key":"2069_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1083032","volume":"14","author":"H Peng","year":"2023","unstructured":"Peng H, Pan L, Ran S, et al. Prediction of MAFLD and NAFLD using different screening indexes: a cross-sectional study in U.S. adults. Front Endocrinol (Lausanne). 2023;14:1083032. https:\/\/doi.org\/10.3389\/fendo.2023.1083032.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2069_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01902-3","volume":"22","author":"H Zou","year":"2023","unstructured":"Zou H, Ma X, Zhang F, Xie Y. Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease. Lipids Health Dis. 2023;22(1):145. https:\/\/doi.org\/10.1186\/s12944-023-01902-3.","journal-title":"Lipids Health Dis"},{"key":"2069_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951689","volume":"13","author":"Y Xue","year":"2022","unstructured":"Xue Y, Xu J, Li M, Gao Y. Potential screening indicators for early diagnosis of NAFLD\/MAFLD and liver fibrosis: triglyceride glucose index-related parameters. Front Endocrinol (Lausanne). 2022;13:951689. https:\/\/doi.org\/10.3389\/fendo.2022.951689.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2069_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101345","volume":"48","author":"B Rivi\u00e8re","year":"2022","unstructured":"Rivi\u00e8re B, Jaussent A, Macioce V, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4):101345. https:\/\/doi.org\/10.1016\/j.diabet.2022.101345.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2069_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01954-5","volume":"22","author":"M Wang","year":"2023","unstructured":"Wang M, Chang M, Shen P, Wei W, Li H, Shen G. Application value of triglyceride-glucose index and triglyceride-glucose body mass index in evaluating the degree of hepatic steatosis in non-alcoholic fatty liver disease. Lipids Health Dis. 2023;22(1):186. https:\/\/doi.org\/10.1186\/s12944-023-01954-5.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2069_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1507\/endocrj.48.81","volume":"48","author":"Y Ikeda","year":"2001","unstructured":"Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001;48(1):81\u20136. https:\/\/doi.org\/10.1507\/endocrj.48.81.","journal-title":"Endocr J"},{"issue":"1","key":"2069_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01802-6","volume":"22","author":"M Ebrahimi","year":"2023","unstructured":"Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 2023;22(1):41. https:\/\/doi.org\/10.1186\/s12944-023-01802-6.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"2069_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"2069_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","volume":"14","author":"MT Long","year":"2016","unstructured":"Long MT, Pedley A, Colantonio LD, et al. Development and validation of the Framingham Steatosis Index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol. 2016;14(8):1172-1180.e2. https:\/\/doi.org\/10.1016\/j.cgh.2016.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2069_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep16494","volume":"5","author":"J Wang","year":"2015","unstructured":"Wang J, Xu C, Xun Y, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015;5(1):16494. https:\/\/doi.org\/10.1038\/srep16494.","journal-title":"Sci Rep"},{"issue":"8","key":"2069_CR16","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21(8):2026\u201339. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.042.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2069_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0154-x","volume":"12","author":"CL Cheung","year":"2014","unstructured":"Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med. 2014;12(1):154. https:\/\/doi.org\/10.1186\/s12916-014-0154-x.","journal-title":"BMC Med"},{"issue":"6","key":"2069_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","journal-title":"Hepatology"},{"issue":"1","key":"2069_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.13012","volume":"41","author":"CE Ruhl","year":"2015","unstructured":"Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41(1):65\u201376. https:\/\/doi.org\/10.1111\/apt.13012.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2069_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01571-x","volume":"17","author":"M Hu","year":"2025","unstructured":"Hu M, Yang J, Gao B, et al. Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus. Diabetol Metab Syndr. 2025;17(1):10. https:\/\/doi.org\/10.1186\/s13098-024-01571-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2069_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01794-z","volume":"24","author":"J Tian","year":"2024","unstructured":"Tian J, Cao Y, Zhang W, et al. The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocr Disord. 2024;24(1):261. https:\/\/doi.org\/10.1186\/s12902-024-01794-z.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2069_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72795-0","volume":"14","author":"Z Yang","year":"2024","unstructured":"Yang Z, Li A, Jiang Y, Maidaiti X, Wu Y, Jin Y. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021. Sci Rep. 2024;14(1):22232. https:\/\/doi.org\/10.1038\/s41598-024-72795-0.","journal-title":"Sci Rep"},{"issue":"5","key":"2069_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022.","journal-title":"J Hepatol"},{"issue":"6","key":"2069_CR24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042.","journal-title":"Gastroenterology"},{"issue":"33","key":"2069_CR25","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"2","key":"2069_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mmr.2020.11175","volume":"22","author":"S Jiang","year":"2020","unstructured":"Jiang S, Young JL, Wang K, Qian Y, Cai L. Diabetic\u2011induced alterations in hepatic glucose and lipid metabolism: the role of type 1 and type 2 diabetes mellitus (Review). Mol Med Rep. 2020;22(2):603\u201311. https:\/\/doi.org\/10.3892\/mmr.2020.11175.","journal-title":"Mol Med Rep"},{"issue":"46","key":"2069_CR27","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3748\/wjg.15.5789","volume":"15","author":"C Lohwasser","year":"2009","unstructured":"Lohwasser C, Neureiter D, Popov Y, Bauer M, Schuppan D. Role of the receptor for advanced glycation end products inhepatic fbrosis. World J Gastroenterol. 2009;15(46):5789\u201398. https:\/\/doi.org\/10.3748\/wjg.15.5789.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2069_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/s2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. The Lancet Gastroenterology & Hepatology. 2023;8(9):829\u201336. https:\/\/doi.org\/10.1016\/s2468-1253(23)00157-7.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2069_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/cjgh\/5871321","volume":"2025","author":"H Zou","year":"2025","unstructured":"Zou H, Xie J, Ma X, Xie Y. The value of TyG-related indices in evaluating MASLD and significant liver fibrosis in MASLD. Can J Gastroenterol Hepatol. 2025;2025:5871321. https:\/\/doi.org\/10.1155\/cjgh\/5871321.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"2069_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.47429\/lmo.2023.13.4.318","volume":"13","author":"P Kj","year":"2023","unstructured":"Kj P. Diagnostic performance of hepatic steatosis algorithms in Korean population with metabolic-associated fatty liver disease. Lab Med Online. 2023;13(4):318\u201323. https:\/\/doi.org\/10.47429\/lmo.2023.13.4.318.","journal-title":"Lab Med Online"},{"issue":"3","key":"2069_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1210\/jc.2011-2272","volume":"97","author":"C Lorenzo","year":"2012","unstructured":"Lorenzo C, Hazuda HP, Haffner SM. Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab. 2012;97(3):793\u20139. https:\/\/doi.org\/10.1210\/jc.2011-2272.","journal-title":"J Clin Endocrinol Metab"},{"key":"2069_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.mce.2014.11.029","volume":"402","author":"BF Palmer","year":"2015","unstructured":"Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015;402:113\u20139. https:\/\/doi.org\/10.1016\/j.mce.2014.11.029.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02069-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:55:59Z","timestamp":1767041759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02069-w","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NHANES was conducted with approval by the National Center for Health Statistics Ethics Review Board, and obtained informed written consent from all the individuals involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"461"}}